Cold medicine hard to sell in the first half of 2020? Revenues at 7 pharmaceutical companies fall more than 10%

According to incomplete statistics, so far, a number of main related respiratory drugs in the company reported a decline in performance, including 7 pharmaceutical companies revenue decline or even more than 10%.
From the semi-annual reports issued by the seven pharmaceutical companies, the main reasons for the large decline in revenue include the limited retail terminal sales due to phased policy control, the decline in the number of outpatient clinics in the department, and so on, resulting in a decline in the demand for related upper respiratory drugs.
Pharmaceuticals: Revenue fell nearly 40% YoY, and the company's 2020 half-year report showed that in the first half of 2020, the company achieved operating income of 300 million yuan, down 37.22% YoY;
said that in the first half of 2020, the company's OTC product sales activities were restricted, coupled with retail pharmacies to buy fever, cough medicine personnel information registration reporting system and other restrictions, customer demand for products decreased, resulting in a significant decline in operating income;
by the combination of the above factors, the company's net profit fell significantly.
: Revenue fell about 30% year-on-year on August 26th, and Sunflower Pharmaceuticals released its semi-annual report.
the first half of 2020, the Company achieved operating income of RMB1.6 billion, down 32.97 percent YoY, and net profit attributable to shareholders of listed companies was RMB237 million, down 22.40% YoY.
Sunflower Pharmaceuticals explained that in the first half of the year, the company's cold, cough, fever, anti-inflammatory products in addition to the national phased policy control led to limited retail terminal sales, hospital terminal patient control, diversion also led to the company's related product sales blocked, at the same time, coupled with long-term suspension and generally enhanced personal protection and other factors, there has been a reduction in the incidence of conventional influenza and other diseases, the corresponding self-diagnosis and treatment of drug demand decline.
East Sunshine, Jichuan Pharmaceuticals and other five pharmaceutical companies revenue fell by about 20%, in addition to Special One Pharmaceuticals, Sunflower Pharmaceuticals, Dongsan, Jichuan Pharmaceuticals, China Resources 39, Kangzhi Pharmaceuticals, Jinshi Ya Pharmaceuticals and other five pharmaceutical companies revenue decline in about 20%.
, Dongsan's revenue fell 19.51 percent from a year earlier, the statement said, mainly due to the decline in sales of pharmaceutical products and chemical products sales and prices during the reporting period.
understood that the company's main products, sales increased from 435 million yuan in 2015 to 6 billion yuan in 2019.
2019, the Covey series of products has contributed more than 95% of the revenue to the manufacturing business segment of Dongsian Pharmaceuticals.
first half of the year, Jichuan Pharmaceuticals achieved revenue of RMB2,951 million, down 24.46% YoY, and net profit of RMB685 million, down 28.94% YoY.
Explain that during the reporting period, the number of outpatient clinics in pediatrics and other departments decreased significantly, while sales at the pharmacy side were also adversely affected, resulting in a decline in the company's operating performance.
first half of the company's operating income of 337 million yuan, down 19.65 percent year-on-year.
the main impact of the decrease in sales revenue of pharmaceutical products during the reporting period, the company said in a statement.
In the industry's view, whether changes in consumer hygiene habits will continue to affect sales of cold and respiratory drugs, especially the impact of the second half of the sales season, still needs to be sustainable.
the decline in sales, a number of pharmaceutical companies are also taking positive measures to deal with.
such as Sunflower Pharmaceuticals in the semi-annual report mentioned that the company will immediately adjust the company's product sales strategy, timely optimize the product sales structure.